Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases
Description
Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body. MeSH
Hierarchy View
Subtype Terms (44)
Aneurysm
29 drugs (27 approved, 2 experimental)
Angiodysplasia
4 drugs (3 approved, 1 experimental)
Angioedema
23 drugs (18 approved, 5 experimental)
Angiomatosis
3 approved drugs
Aortic Diseases
30 drugs (25 approved, 5 experimental)
Arterial Occlusive Diseases
93 drugs (68 approved, 25 experimental)
Arteriovenous Malformations
10 drugs (8 approved, 2 experimental)
Capillary Leak Syndrome
2 drugs (1 approved, 1 experimental)
Cerebrovascular Disorders
62 drugs (44 approved, 18 experimental)
Diabetic Angiopathies
8 drugs (6 approved, 2 experimental)
Embolism and Thrombosis
11 drugs (10 approved, 1 experimental)
Hemorrhoids
52 drugs (27 approved, 25 experimental)
Hemostatic Disorders
4 drugs (1 approved, 3 experimental)
Hepatic Veno-Occlusive Disease
3 approved drugs
Hyperemia
8 drugs (6 approved, 2 experimental)
Hypertension
540 drugs (263 approved, 277 experimental)
Hypotension
120 drugs (88 approved, 32 experimental)
Mesenteric Ischemia
1 approved drug
Myocardial Ischemia
179 drugs (119 approved, 60 experimental)
Optic Neuropathy, Ischemic
23 drugs (18 approved, 5 experimental)
Peripheral Vascular Diseases
72 drugs (34 approved, 38 experimental)
Prehypertension
45 drugs (28 approved, 17 experimental)
Pulmonary Veno-Occlusive Disease
3 approved drugs
Reperfusion Injury
80 drugs (60 approved, 20 experimental)
Retinal Vein Occlusion
44 drugs (28 approved, 16 experimental)
Stenosis, Pulmonary Vein
1 approved drug
Telangiectasis
8 drugs (4 approved, 4 experimental)
Thoracic Outlet Syndrome
2 drugs (1 approved, 1 experimental)
Varicocele
4 approved drugs
Varicose Veins
21 drugs (10 approved, 11 experimental)
Vascular Neoplasms
1 approved drug
Vascular System Injuries
6 drugs (1 approved, 5 experimental)
Vasculitis
38 drugs (26 approved, 12 experimental)
Vasoplegia
12 drugs (11 approved, 1 experimental)
Venous Insufficiency
18 drugs (4 approved, 14 experimental)
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (42)
Phase 3 Indicated Drugs (25)
Phase 2 Indicated Drugs (37)
Phase 1 Indicated Drugs (5)
Other Experimental Indicated Drugs (40)
Organization Involved with Phase 4 Indications (78)
Aristotle University of Thessaloniki
Association for Innovation and Biomedical Research on Light and Image (AIBILI)
Barnsley Hospital NHS Foundation Trust
European Vision Institute Clinical Research Network
Fundação de Amparo à Pesquisa do Estado de São Paulo
Helena Laboratories Point of Care
Hoosier Cancer Research Network
Icahn School of Medicine at Mount Sinai
King Fahad Armed Forces Hospital
Lepu Medical Technology (Beijing) Co., Ltd.
Los Angeles Biomedical Research Institute
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Organization Involved with Phase 3 Indications (81)
Asheville Cardiology Associates
Beijing Northland Biotech. Co., Ltd.
Brazilian Clinical Research Institute
Canadian Institutes of Health Research (CIHR)
Case Western Reserve University
Heart and Stroke Foundation of Canada
Jacksonville Center for Clinical Research
Katholieke Universiteit Leuven
National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH)
National Health and Medical Research Council, Australia
Oregon Health and Science University
Russian Academy of Medical Sciences
SMT KASHIBAI NAVALE MEDICAL COLLEGE
Statistics and Epidemiology Research Corporation
University of Alabama, Birmingham
Organization Involved with Phase 2 Indications (74)
MultiGene Vascular Systems Ltd.
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Aging (NIA)
St. Antonius Hospital, Nieuwegein
Translational Research Informatics Center, Kobe, Hyogo, Japan
Organization Involved with Phase 1 Indications (16)
Organization Involved with Other Experimental Indications (28)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
